Liang Chen - Immunologie, AbbVie, Inc

基本信息

浏览量：5

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 13 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

N12 the Experience of Post-traumatic Growth Process in Newly Diagnosed Chinese Patients with Crohn’s Disease: A Longitudinal Qualitative Study

L Chen, Y Zhou, J Liu

Journal of Crohn's and Colitisno. Supplement_1 (2024)

引用0浏览0引用

P185 Long-term Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis Refractory to Biologic Therapies: 2-Year Results from the Phase 3 SELECT-PsA 2 Study

Philip J Mease,Arathi Setty,Kim Papp,Filip Van den Bosch,Shigeyoshi Tsuji,Mauro Keiserman,Xianwei Bu,Liang Chen,Reva Mccaskill,Erin Mcdearmon-Blondell,Peter Wung,William Tillett

Rheumatologyno. Supplement_2 (2023)

引用0浏览0引用

Targeting Dendritic Cell Inhibitory Receptors to Down Regulate Immune Response in Inflammatory Disease

Hsi-Ju Wei,Liang Chen, Suresh Patil,Jeffrey Barbon,James Waire,Donna McCarthy,Arun Deora,Stephen Laroux, Liang Jin, Yu Tian, Trudi Veldman,Tariq Ghayur,Subramanya Hegde

JOURNAL OF IMMUNOLOGYno. 1 (2023)

引用0浏览0引用

Efficacité Et Tolérance À Long Terme De L’upadacitinib Chez Les Patients Présentant Un Rhumatisme Psoriasique Réfractaire Aux Traitements Biologiques : Résultats À 2 Ans De L’étude De Phase III SELECT-PsA 2

P.J. Mease,A. Setty,K. Papp,F. Van Den Bosch,S. Tsuji,M. Keiserman,X. Bu,L. Chen,R. Mccaskill,E. McDearmon-Blondell,P. Wung,P. Richette,W. Tillett

Revue du Rhumatisme (2022): A185-A186

引用0浏览0引用

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study

Iain B. McInnes,Koji Kato,Marina Magrey,Joseph F. Merola,Mitsumasa Kishimoto,Derek Haaland,Liang Chen,Yuanyuan Duan,Jianzhong Liu,Ralph Lippe,Peter Wung

Rheumatology and Therapy（2022）

引用24浏览0WOS引用

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

Iain B. McInnes,Jaclyn K. Anderson,Marina Magrey,Joseph F. Merola,Yi Liu,Mitsumasa Kishimoto,Slawomir Jeka,Cesar Pacheco-Tena,Xin Wang,Liang Chen,Patrick Zueger,John Liu,Aileen L. Pangan,Frank Behrens

New England Journal of Medicine（2021）

引用180浏览0WOS引用

180

P173 Efficacy and Safety of Upadacitinib Versus Placebo and Adalimumab in Patients with Active PsA and Inadequate Response to Non-Biologic DMARDs (SELECT-PSA-1): a Double-Blind, Randomised Controlled Phase III Trial

Iain McInnes,Jaclyn Anderson,Marina Magrey,Joseph F. Merola,Yi Liu,Mitsumasa Kishimoto,Slawomir Jeka,Cesar Pacheco-Tena,Xin Wang,Liang Chen,Patrick Zueger,Aileen Pangan,Frank Behrens

Rheumatologyno. Supplement_1 (2021)

引用0浏览0引用

Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis: Results at 56 Weeks from the SELECT-PsA 1 Study

Iain McInnes,Koji Kato,Marina Magrey,Joseph Merola,Mitsumasa Kishimoto,Cesar Pacheco Tena,Derek Haaland,Liang Chen,Yuanyuan Duan,Patrick Zueger,Jianzhong Liu,Ralph Lippe,Aileen Pangan,Frank Behrens

Annals of the rheumatic diseases（2021）

引用5浏览0引用

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

Seattle Rheumatology AssociatesSwedish Medical Center,Lertratanakul Apinya,Papp Kim A.,van den Bosch Filip E.,Tsuji Shigeyoshi, Medical Plus, s.r.o.,Keiserman Mauro W.,Bu Xianwei,Chen Liang,McCaskill Reva M.,Zueger Patrick,McDearmon-Blondell Erin L.,Pangan Aileen L., University of Bath

Rheumatology and Therapy（2021）

引用52浏览0WOS引用

OP0050 ADALIMUMAB INTRODUCTION VERSUS METHOTREXATE DOSE ESCALATION IN PATIENTS WITH INADEQUATELY CONTROLLED PSORIATIC ARTHRITIS: RESULTS FROM RANDOMIZED PHASE 4 CONTROL STUDY

L. C. Coates,W. Tillett,M. A. D’agostino,P. Rahman,F. Behrens,P. G. Conaghan,E. Mcdearmon-Blondell,X. Bu,L. Chen,M. Kapoor,P. J. Mease

Annals of the Rheumatic Diseases（2020）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn